Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab Monotherapy in Middle Eastern Psoriasis Patients
NCT00687362Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2006
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of infliximab in plaque psoriasis, sponsored by Merck & Co. Primary endpoint: Psoriasis Area and Severity Index 75 Response at 10 weeks. Started May 2006; status: completed.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00687362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687362.